The Effects of Oxytocin on Craving, Mental Health Parameters, and Stress Hormones in Methamphetamine-Dependent Patients Undergoing Matrix Treatment Model: A Randomized, Double-Blind Clinical Trial.

Azadbakht A, Salehi M, Maracy MR, Banafshe HR

European addiction research2 Aug 2022Cited by 8 (Europe PMC)

PMID35917806DOI10.1159/000525443PepBankPUB-35917806

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In methamphetamine-dependent patients, 4 weeks of intranasal oxytocin improved craving scores compared with placebo.
In plain wordsIn people dependent on methamphetamine, nasal oxytocin for 4 weeks improved craving scores more than placebo.
Peptide
Oxytocin
Outcome
DecreaseCraving score
Study
n = 42
Comparator
Normal saline placebo
Outcome group
Addiction, withdrawal and alcohol intake · Mental health and mood
Studied dose
40 IU · intranasal · 4 weeksAs given in this study (human).
Source sentences
Summary
Our findings indicated that OXT administration for 4 weeks is associated with a significant improvement in the craving and depression scores, respectively (p < 0.001 and p < 0.001), but there was no significant difference for anxiety scores compared with the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
This randomized placebo-controlled clinical trial was conducted in 42 METH-dependent patients undergoing MTM to receive either intranasal OXT 40 IU (n = 21) or normal saline as placebo (n = 21) for 4 weeks.
Report a problemFND-3591780601
02HumanRandomized controlled trialEfficacy outcome
In methamphetamine-dependent patients, 4 weeks of intranasal oxytocin improved depression scores compared with placebo.
In plain wordsIn people dependent on methamphetamine, nasal oxytocin for 4 weeks improved depression scores more than placebo.
Peptide
Oxytocin
Outcome
DecreaseDepression score
Study
n = 42
Comparator
Normal saline placebo
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
40 IU · intranasal · 4 weeksAs given in this study (human).
Source sentences
Summary
Our findings indicated that OXT administration for 4 weeks is associated with a significant improvement in the craving and depression scores, respectively (p < 0.001 and p < 0.001), but there was no significant difference for anxiety scores compared with the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
This randomized placebo-controlled clinical trial was conducted in 42 METH-dependent patients undergoing MTM to receive either intranasal OXT 40 IU (n = 21) or normal saline as placebo (n = 21) for 4 weeks.
Report a problemFND-3591780602
03HumanRandomized controlled trialEfficacy outcome
In methamphetamine-dependent patients, intranasal oxytocin did not significantly change anxiety scores compared with placebo.
In plain wordsIn people dependent on methamphetamine, nasal oxytocin did not change anxiety scores compared with placebo.
Peptide
Oxytocin
Outcome
No significant changeAnxiety score
Study
n = 42
Comparator
Normal saline placebo
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
40 IU · intranasal · 4 weeksAs given in this study (human).
Source sentences
Summary
Our findings indicated that OXT administration for 4 weeks is associated with a significant improvement in the craving and depression scores, respectively (p < 0.001 and p < 0.001), but there was no significant difference for anxiety scores compared with the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
This randomized placebo-controlled clinical trial was conducted in 42 METH-dependent patients undergoing MTM to receive either intranasal OXT 40 IU (n = 21) or normal saline as placebo (n = 21) for 4 weeks.
Report a problemFND-3591780603
04HumanRandomized controlled trialEfficacy outcome
In methamphetamine-dependent patients, intranasal oxytocin decreased cortisol levels compared with placebo.
In plain wordsIn people dependent on methamphetamine, nasal oxytocin lowered cortisol levels more than placebo.
Peptide
Oxytocin
Outcome
DecreaseCortisol level
Study
n = 42
Comparator
Normal saline placebo
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
40 IU · intranasal · 4 weeksAs given in this study (human).
Source sentences
Summary
In addition, OXT administration significantly decreased cortisol (p < 0.001) and ACTH levels (p < 0.002).
1 context sentence(design, population, supporting numbers)
Summary · context
This randomized placebo-controlled clinical trial was conducted in 42 METH-dependent patients undergoing MTM to receive either intranasal OXT 40 IU (n = 21) or normal saline as placebo (n = 21) for 4 weeks.
Report a problemFND-3591780604
05HumanRandomized controlled trialEfficacy outcome
In methamphetamine-dependent patients, intranasal oxytocin decreased ACTH levels compared with placebo.
In plain wordsIn people dependent on methamphetamine, nasal oxytocin lowered ACTH levels more than placebo.
Peptide
Oxytocin
Outcome
DecreaseACTH level
Study
n = 42
Comparator
Normal saline placebo
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
40 IU · intranasal · 4 weeksAs given in this study (human).
Source sentences
Summary
In addition, OXT administration significantly decreased cortisol (p < 0.001) and ACTH levels (p < 0.002).
1 context sentence(design, population, supporting numbers)
Summary · context
This randomized placebo-controlled clinical trial was conducted in 42 METH-dependent patients undergoing MTM to receive either intranasal OXT 40 IU (n = 21) or normal saline as placebo (n = 21) for 4 weeks.
Report a problemFND-3591780605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 02:48 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.